A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Key Inclusion Criteria:

• Male or female sex; ≥18 years of age at Day 1/Baseline (Visit 2)

• May have been previously enrolled in PLATYPUS Part B (Protocol #VP001-CL101) orWALLABY (Protocol #VP001-CL102) study. At Screening Visit in this study,participants must have completed at least 8 weeks after last study agentadministration in PLATYPUS Part B (Protocol #VP001-CL101) or WALLABY (Protocol #VP001-CL102) study

• Have a confirmed clinical diagnosis of Retinitis Pigmentosa.

• Have a confirmed genetic diagnosis of Retinitis Pigmentosa secondary to mutation inthe PRPF31 gene.

• For participants not previously enrolled in VP001-CL101 or VP001-CL102 studies: Meetall of the following for visual function in the study eye at the Screening Visit:

1. Mean microperimetry threshold: >5 decibel (dB) to <15 dB

2. Ellipsoid zone (EZ) length >1000 microns of which 500 microns is contiguous, bySD-OCT

3. In the opinion of the Investigator, rod function is observed in any direction >10 degrees per static perimetry at Screening Visit (Visit 1)

Key Exclusion Criteria:

• Have any uncontrolled systemic disease that, in the opinion of the Investigator,would preclude participation in the study that include but are not limited toinfection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemiccontrol issues, or any other medical condition that may put the participant at riskdue to study procedures.

• Known mutations in genes that cause autosomal dominant RP, X-linked RP, or presenceof biallelic mutations in autosomal recessive RP/retinal dystrophy genes other thanPRPF31 mutations.

• Have used anti-VEGF agents within 2 months or corticosteroid injections within thelast 3 months.

• Have had Ozurdex® implants placed within 3 months or Retisert® or Iluvien® implantsplaced within 3 years prior to Baseline (Visit 2).

• Within 3 months prior to Baseline (Visit 2), have undergone any vitreoretinalsurgery or any other ocular surgery

• Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmicevaluation or photography, as assessed by the investigator.

• Have used any investigational drug or device within 90 days or 5 estimatedhalf-lives (or within 60 days from last administration of VP-001 in the VP001-CL101Part B or VP001-CL102 studies) of Baseline (Visit 2), whichever is longer,

• Have a recent history (<6 months) or current excessive recreational drug or alcoholuse, in the opinion of the investigator.